Clinical late phase II trials of MultiHance® (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan

Journal of Computer Assisted Tomography

Volumn 23, Issue SUPPL., 1999, Pages

  Kuwatsuru, Ryohei ^a   Kadoya, Masumi ^b   Ohtomo, Kuni ^b   Tanimoto, Akihiro ^b   Hirohashi, Shinji ^b   Murakami, Takamichi ^b   Tanaka, Yutaka ^b   Yoshikawa, Kohki ^b   Katayama, Hitoshi ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Contrast media; Gadolinium; Gd BOPTA; Liver; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIA; GADOLINIUM; GADOLINIUM COMPOUNDS; LIVER; MAGNETISM; RESONANCE; SPIN POLARIZATION; TUMORS;

BREATH-HOLD; CLASSIFIEDS; CONTRAST MEDIUM; DYNAMIC PHASE; GADOLINIA; GD-BOPTA; GRADIENT ECHO SEQUENCES; LIVER IMAGING; LIVER TUMORS; T1-WEIGHTED;

MAGNETIC RESONANCE IMAGING;

GADOBENATE DIMEGLUMINE;

CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; URTICARIA;

EID: 0033394616     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199911001-00010     Document Type: Conference Paper

References (20)

1. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798-809.
2. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282-91.
3. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol 1997;32:780-96.
4. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. Gd-BOPTA clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5:S86-9.
5. Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J. Gadobenate dimeglumine - a new contrast agent for MR imaging: Preliminary Evaluation in Healthy Volunteers. AJR 1992;157:887-92.
6. Caudana R, Morana G, Pirovano G, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1996;199:513-20.
7. Hamm B, Bassi AM, Grazioli L et al. MultiHance®-enhanced dynamic and delayed MR imaging in the detection and characterization of focal liver lesions. In: Proceedings of The International Society for Magnetic Resonance in Medicine. Vancouver: 1997,p67 [Abstract].
8. Kuwatsuru R, Kadoya M, Tanimoto A, Hirohashi S, Katayama H. Early phase II trial of Gd-BOPTA (E7155) for the MR imaging of liver tumors. Nippon Acta Radiologica 1996;56:555-63 (in Japanese).
9. Vittadini G, Felder E, Tirone P, Lorusso V. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988;23:S246-8.
10. Vittadini G, Felder E, Musu C, Tirone P. Preclinical profile of Gd-BOPTA - a liver-specific MRI contrast agent. Invest Radiol 1990; 25:S59-60.
11. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. JMRI 1993;3:179-86.
12. Mirowitz SA, Lee JKT, Gutierrez E, Brown JJ, Heiken JP, Eilenberg SS. Dynamic gadolinium-enhanced rapid acquisition spin-echo MR imaging of the liver. Radiology 1991;179:371-6.
13. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190:417-23.
14. Ito K, Choji T, Nakada T, Nakanishi T, Kurokawa F, Okita K. Multislice dynamic MRI of hepatic tumors. J Comput Assist Tomogr 1993;17:390-6.
15. Runge VM, Lee C, Williams NM. Detectability of small liver metastases with gadolinium BOPTA. Invest Radiol 1997;32:557-65.
16. Hamm B, Mahfouz AE, Taupitz M, et al. Liver Metastases: Improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-82.
17. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-8.
18. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704-10.
19. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging and pathological findings. Invest Radiol 2000 In press.
20. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. JMRI 1998;8:862-7.